Oxford BioDynamics biomarker platform is selected to help identify COVID-19 patients at risk of severe disease and profile patients who will benefit from therapeutic treatment
Drug Discovery Today
MAY 1, 2020
Oxford BioDynamics’ EpiSwitch technology has been chosen as the biomarker platform for prognostic and predictive profiling of COVID-19 patients in the GETAFIX clinical study.Institute of Infection, Immunity and Inflammation, University of Glasgow, and NHS Scotland are leading the effort to identify patients at risk of severe immune complications and those patients who can benefit from treatment with the anti-viral favipiravir.The EpiSwitch platform has already delivered prognostic and predictive
Let's personalize your content